CTRI/2023/06/054242
Completed
未知
A study to evaluate the Safety and efficacy of the TonEQ for Spot Reduction, Even Skin Tone and Skin Health improvement in healthy subjects. - NI
Transformative Learning Solutions Pvt Ltd0 sites75 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Transformative Learning Solutions Pvt Ltd
- Enrollment
- 75
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Female adult subjects in general good health as determined from a re\-cent medical history, general physical examination, dermatological as\-sessment.
- •2\.Subjects in the age group of 40\-60 years (both ages inclusive).
- •Subject with Fitzpatrick skin types III to V
- •3\.Each subject should have hyperpigmentary regions (may or at least one spot of 3mm size)
- •4\. Subject free of excessive hair, acne, cuts, abrasions, fissures, wounds, lacerations, or any other active skin conditions on the face.
- •5\.Subject who agrees not to use any other product/treatment/home remedy/ except the provided products on their face during the study period other than the test product.
- •6\.Subjects who agree not to carry out bleaching or any other procedures in\-cluding facial etc. on face during the study period.
- •7\.Subjects who agree not to expose to excessive sun light. (Sun exposure not more than half an hour daily and during that time use of umbrella to cover face).
- •8\.Subjects willing to give a voluntary written informed consent, photog\-raphy release and agree to come for regular follow\-up.
- •9\.Subjects willing to abide by and comply with the study protocol.
Exclusion Criteria
- •1\. Subject with any other signs of significant local irritation or skin disease.
- •2\.Subject currently taking any medication, which the Investigator believes may influence the interpretation of the data.
- •3\.Subject having clinically significant systemic or cutaneous disease, chronic illness or had major surgery in the last year.
- •4\.Subjects who do not agree to remove all jewelry on/around face (e.g., necklace, earrings, if possible, nose ring), during Digital imaging.
- •5\.Subjects having hair style which covers almost the entire forehead
- •6\.Subjects undergoing any treatment of any skin condition on their face/forearm.
- •Subjects not willing to discontinue other topical facial products.
- •7\.Subject allergic or sensitive to bar cleansing products, cosmetics, creams/lotions, artificial jewellery or anything else.
- •8\.Pregnant women (as confirmed by UPT) and lactating women
- •9\.Subjects on any medical treatment either systemic/topical in the past 1 month or currently taking medication including food supplements.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Study to Evaluate the Safety and efficacy of the Antibody APX005M in Adult Patients with Metastatic Melanoma Who have not Received Prior Immunotherapynresectable or metastatic melanomaMedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-003864-30-ESApexigen, Inc.36
Active, not recruiting
Phase 1
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanomaon-small Cell Lung Cancer and Metastatic MelanomaMedDRA version: 20.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-003866-14-ESApexigen, Inc.174
Active, not recruiting
Phase 1
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanomaon-small Cell Lung Cancer and Metastatic MelanomaMedDRA version: 20.0Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-003866-14-FRApexigen, Inc.174
Active, not recruiting
Not Applicable
A study to determine the safety and efficacy of a terbinafine topical formulation system in subjects with onychomycosis in laser treated toenails versus ciclopirox lacquer in intact toenailsDistal/lateral Subungual onychomycosis (DSO) caused by dermatophytesMedDRA version: 8.1Level: LLTClassification code 10030338Term: OnychomycosisEUCTR2006-005895-42-ISTLT Medical Ltd.235
Completed
Not Applicable
Safety and effectiveness of TOPS™ SystemSingle Level Lumbar Spine Stenosis (with up to a grade 1 spondylolisthesis)SurgeryISRCTN47205504Premia Spine Ltd (Israel)10